Complications of myeloma and its treatments

Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies. Jakubowiak AJ et al. Hematology. 2017 May 25:1-7. doi: 10.1080/10245332.2017.1328165. [Epub ahead of print]. Clinical conditions responsible for hyperviscosity and skin ulcers complications. Caimi G et al. Clin Hemorheol Microcirc. 2017 May 19. doi: 10.3233/CH-160218. [Epub ahead of print]. Increased risk of arterial thromboembolic events with combination…

Current treatments

Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously UntreatedMyeloma Patients Eligible for Transplants. Chen JF et al. Acta Haematol. 2017 May 5;137(4):207-208. doi: 10.1159/000471839. [Epub ahead of print]. Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV). Tessenow…

Related conditions

IgG4-related disease with bone marrow involvement mimicking multiple myeloma. Tang SH et al. Br J Haematol. 2017 Apr 25. doi: 10.1111/bjh.14651. [Epub ahead of print]. Impact of Autologous Stem Cell Transplantation on the Incidence and Outcome of Oligoclonal Bands in Patients with Light-Chain Amyloidosis. Rodríguez-Lobato LG et al. Biol Blood Marrow Transplant. 2017 Apr 18. pii: S1083-8791(17)30400-7. doi: 10.1016/j.bbmt.2017.04.012. [Epub ahead of print]. Crystalglobulinemia manifesting as chronic arthralgia…

Emerging treatments

Phase I trial of systemic administration of edmonston strain of measles virus, genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Dispenzieri A et al. Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.120. [Epub ahead of print]. Moving beyond maximum tolerated dose for targeted oncology drugs: Use of clinical utility index to optimize venetoclax…

Biology and genetics

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Mishima Y et al. Cell Rep. 2017 Apr 4;19(1):218-224. doi: 10.1016/j.celrep.2017.03.025. Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma. Dupéré-Richer D et al. Curr Opin Hematol. 2017 Apr 22. doi: 10.1097/MOH.0000000000000358. [Epub ahead of print]. Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple…

General

Daratumumab for the treatment of multiple myeloma. Touzeau C et al. Expert Opin Biol Ther. 2017 Apr 24. doi: 10.1080/14712598.2017.1322578. [Epub ahead of print]. New developments in the treatment of multiple myeloma – clinical utility of daratumumab. McEllistrim C et al. Biologics. 2017 Apr 11;11:31-43. doi: 10.2147/BTT.S97633. eCollection 2017. Immunologic approaches for the treatment of multiple myeloma. Rasche L et al. Cancer Treat Rev. 2017 Apr 6;55:190-199. doi: 10.1016/j.ctrv.2017.03.010. [Epub ahead of print]. Which…

Supportive treatments

Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Richardson PG et al. Br J Haematol. 2017 Apr 26. doi: 10.1111/bjh.14727. [Epub ahead of print]. Trends in vertebral augmentation for spinal fractures in myeloma patients: a 2002-2012 population-based study using a large national cancer registry. Chokshi FH et al. J Neurointerv Surg. 2017 Apr…

Complications of myeloma and its treatments

Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. Lee SE et al. Anticancer Drugs. 2017 Apr 20. doi: 10.1097/CAD.0000000000000506. [Epub ahead of print]. Paraneoplastic acute disseminated encephalomyelitis associated with multiple myeloma. Law LY et al. Mult Scler Relat Disord. 2017 Apr;13:21-24. doi: 10.1016/j.msard.2017.01.013. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD):…

Current treatments

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Bahlis NJ et al. Leukemia. 2017 Apr 4. doi: 10.1038/leu.2017.111. [Epub ahead of print]. Lenalidomide, adriamycin, dexamethasone (RAD) for induction followed by stem-cell transplant in newly diagnosed myeloma. Knop S et al. Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.124. [Epub ahead of print]. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation…